172 related articles for article (PubMed ID: 7772507)
21. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
22. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
23. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
[TBL] [Abstract][Full Text] [Related]
24. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
25. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
[TBL] [Abstract][Full Text] [Related]
28. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Yamada O; Ichikawa M; Okamoto T; Park C; Motoji T; Mizoguchi H; Shibuya A
Br J Haematol; 2001 Apr; 113(1):153-60. PubMed ID: 11328295
[TBL] [Abstract][Full Text] [Related]
29. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
30. Antibody-directed superantigen-mediated T-cell killing of myeloid leukaemic cell line cells.
Gidlöf C; Carlson B; Dohlsten M; Tötterman TH
Eur J Haematol; 1998 Apr; 60(4):233-9. PubMed ID: 9579876
[TBL] [Abstract][Full Text] [Related]
31. Regulation of human natural cytotoxicity by IgG. IV. Association between binding of monomeric IgG to the Fc receptors on large granular lymphocytes and inhibition of natural killer (NK) cell activity.
Sulica A; Galatiuc C; Manciulea M; Bancu AC; DeLeo A; Whiteside TL; Herberman RB
Cell Immunol; 1993 Apr; 147(2):397-410. PubMed ID: 8453679
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
33. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
Xie Z; Shi M; Feng J; Yu M; Sun Y; Shen B; Guo N
Biochem Biophys Res Commun; 2003 Nov; 311(2):307-12. PubMed ID: 14592414
[TBL] [Abstract][Full Text] [Related]
34. Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R.
Connor RI; Dinces NB; Howell AL; Romet-Lemonne JL; Pasquali JL; Fanger MW
Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9593-7. PubMed ID: 1835086
[TBL] [Abstract][Full Text] [Related]
35. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
[TBL] [Abstract][Full Text] [Related]
36. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
[TBL] [Abstract][Full Text] [Related]
37. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
38. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
39. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
40. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
